Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Mol Cancer Res. 2011 Feb 25;9(4):403–417. doi: 10.1158/1541-7786.MCR-10-0133

Figure 1.

Figure 1

Figure 1

Figure 1

TRA-8-induced cytotoxicity against breast cancer cell lines was enhanced by doxorubicin or bortezomib pretreatment. Cells (1000/well) were plated in 96 well plates and incubated at 37 °C for 24 h. (A) Cells were then exposed to varying concentrations of TRA-8 for 24 h. For combination treatment, cells were pretreated with various doses of doxorubicin (B) or bortezomib (C) for 24 h, followed by TRA-8 treatment for an additional 24 h. Cell viability was determined using the ATPLite assay. Data obtained was analyzed to determine the combination index (CI) as a measure of drug interaction. CI values < 1 indicate synergism, CI values = 1 indicate additive effect, and CI values > 1 indicate antagonism.